Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Allarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...
pharmaphorum6d
AZ aims at Pfizer, GSK with potential new PARP cancer drug
AZ has been presenting preclinical data from AZD5305, its next-generation PARP1 inhibitor at the 2021 American Association for Cancer Research meeting, which the company thinks could be more ...
eLife16h
Genome organization by SATB1 binding to base-unpairing regions (BURs) provides a scaffold for SATB1-regulated gene expression
This important study has modified ChIP-seq and 4C-seq procedures with a urea step and shows that this drastically changes the pattern of chromatin interactions observed for SATB1 but not other ...
The EMBO Journal6d
MIA40 suppresses cell death induced by apoptosis-inducing factor 1
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Mitochondria harbor respiratory complexes that ...
Yahoo Finance6d
BeiGene, Ltd. (6160.HK)
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.